Providence Therapeutics announces exec appointment

Canadian mRNA-focussed biotech firm Providence Therapeutics today announced the appointment of Robert Georgantas III as president and chief technology officer (CTO).

“Robert’s experience in drug discovery, clinical development, and management at the executive level across several biotech and large pharmaceutical companies will be invaluable as we continue advancing our pipeline of mRNA vaccines,” said Brad Sorenson, chief executive of Providence Therapeutics. “With the expansion of our pipeline of mRNA vaccines for cancer and infectious diseases and our COVID-19 vaccine candidate moving forward into Phase III trials this year, Robert’s insights will be crucial from a strategic and technical advancement perspective,” he added.

Dr Georgantas brings over 16 years of experience in the pharmaceutical industry. He most recently served as chief scientific officer of Biodesix, a biopharmaceutical company, where he was responsible for building and implementing the scientific strategy across the company, as well as product development activities and commercialization of the company’s pipeline products. He additionally contributed to clinical development and medical affairs activities, participating in the design and statistical analysis of multiple clinical studies.